
Frontline blinatumomab, ponatinib spares chemotherapy, transplant for patients with newly diagnosed Ph–positive B-ALL
Frontline treatment with blinatumomab plus ponatinib yielded deep, durable remissions in patients with Philadelphia–positive B-cell acute lymphoblastic leukemia, according to updated follow-up results from a phase 2 trial.





